DOCU vs ZYME · P/E 15, rev $2.98B vs rev $76.3M
DocuSign Inc (DOCU) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
DocuSign Inc (DOCU) is a software - application company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported DOCU revenue for 2025-01-31 was $2.98B. Net income was $1.07B. Revenue was up 7.8% from 2024-01-31 to 2025-01-31. DOCU currently screens at market cap $15.74B and trailing P/E 14.8.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
DOCU currently screens at market cap $15.74B and trailing P/E 14.8. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the DOCU and ZYME stock pages for the full models.
Not investment advice.